Viatris' first-ever interchangeable insulin biosimilar preferred on express scripts' largest formulary

Pittsburgh, oct. 20, 2021 /prnewswire/ -- viatris inc. (nasdaq: vtrs) is proud to confirm that express scripts, a leading pharmacy benefit management organization, will list viatris' interchangeable biosimilar semglee® (insulin glargine-yfgn) injection as a preferred insulin brand on its national preferred formulary® (npf), which includes more than 28 million lives. broad coverage of viatris' interchangeable biosimilar by express scripts will help ensure that the many patients in the express scripts network who need insulin may receive the full benefits of and access to treatment with lower or maintained out-of-pocket costs.
VTRS Ratings Summary
VTRS Quant Ranking